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Abstract 
Objective: Genome-wide association studies (GWAS) have been successful at identifying 
associations with stroke and stroke subtypes, but have not yet identified any associations 
solely with small vessel stroke (SVS). SVS comprises a quarter of all ischaemic stroke and is 
a major manifestation of cerebral small vessel disease, the primary cause of vascular 
cognitive impairment. Studies across neurological traits have shown younger onset cases 
have an increased genetic burden. We leveraged this increased genetic burden by 
performing an age-at-onset informed GWAS meta-analysis, including a large younger onset 
SVS population, to identify novel associations with stroke.  
Methods: We used a three-stage age-at-onset informed GWAS to identify novel genetic 
variants associated with stroke. On identifying a novel locus associated with SVS, we 
assessed its influence on other small vessel disease phenotypes, as well as on mRNA 
expression of nearby genes, and on DNA methylation of nearby CpG sites in whole blood 
and in the fetal brain. 
Results: We identified an association with SVS in 4,203 cases and 50,728 controls on 
chromosome 16q24.2 (OR(95% CI)=1.16(1.10-1.22); p=3.2x10-9). The lead SNP 
(rs12445022) was also associated with cerebral white matter hyperintensities (OR(95% 
CI)=1.10(1.05-1.16); p=5.3x10-5; N=3,670), but not intracerebral haemorrhage (OR(95% 
CI)=0.97(0.84-1.12); p=0.71; 1,545 cases, 1,481 controls). rs12445022 is associated with 
mRNA expression of ZCCHC14 in arterial tissues (p=9.4x10-7), and DNA methylation at 
probe cg16596957 in whole blood (p=5.3x10-6).  
Interpretation: 16q24.2 is associated with SVS. Associations of the locus with expression of 
ZCCHC14 and DNA methylation suggest the locus acts through changes to regulatory 
elements.  
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Introduction 
Genome-wide association studies (GWAS) enable identification of common genetic variants 
that influence disease risk and have proved successful in elucidating pathophysiological 
mechanisms underlying diseases with a genetic influence.1 A number of GWAS associations 
have recently been identified with ischaemic stroke, almost all of which have been 
associated with specific stroke subtypes.2-4 A number of genetic associations have been 
reported with cardioembolic (CE) and large artery stroke (LAS), but in contrast there have 
been no robust associations solely with small vessel stroke (SVS). This is despite 
epidemiological data that suggest genetic factors are particularity important for SVS. For 
example, there are a number of monogenic stroke disorders associated with SVS,5 and 
family history studies have shown a strong association between SVS and a family history of 
stroke.6 Similarly, related traits, including white matter hyperintensities, have been shown to 
have high heritability.7 
 
SVS itself comprises a quarter of all ischaemic stroke and is one of the clinically overt 
manifestations of cerebral small vessel disease (SVD), the major cause of vascular cognitive 
impairment. Other radiological features of SVD include white matter hyperintensities (WMH) 
best seen on T2-weighted MRI, cerebral microbleeds - seen on gradient echo MRI, and 
intracerebral hemorrhages (ICH).8 Despite its importance, the pathogenesis of SVD remains 
poorly understood and this limits the development of proven treatments for established 
disease.   
 
One consistent finding across adult-onset neurological complex diseases including 
Parkinson’s disease,9 Alzheimer’s disease,10 and stroke,11 is that younger onset cases have 
a stronger genetic burden from common disease-associated SNPs. Leveraging this 
increased burden, by focussing on younger onset cases in analysis of genetic data, can lead 
This article is protected by copyright. All rights reserved.
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to detection of novel trait-associated variants.11 This may be particularly relevant for SVS, as 
epidemiological studies have shown stronger associations with SVS and a family history of 
stroke in younger stroke cases.6 
 
Here, we perform an age-at-onset informed GWAS meta-analysis in stroke, including a large 
population of younger onset (age<70) small vessel stroke (SVS) cases. We perform analysis 
for all ischaemic stroke (IS) and its three subtypes: cardioembolic (CE), large artery stroke 
(LAS) and SVS. Using this approach we identify a novel association with SVS, seek further 
validation of the locus in other SVD phenotypes, and assess the influence of SNPs at the 
locus on mRNA expression of nearby genes and DNA methylation at nearby CpG sites. 
 
Methods 
Study design 
We employed a three-stage design for the association analysis (Figure 1). In brief, in stage I 
we performed association analysis of stroke phenotypes in 10,210 cases and 12,285 
controls of European ancestry from Europe, United States, and Australia; most of which 
contributed to the METASTROKE ischaemic stoke GWAS meta-analysis – and all of which 
have been described previously (Table 1). 2, 12, 13 In all cases, diagnosis of stroke was based 
on clinical evaluation with radiological confirmation. Subtyping of stroke cases was based on 
the TOAST criteria; in this analysis we considered the CE, LAS and SVS subtypes.14 Of 
note, our SVS analysis included a large sample (1,012 cases, 970 controls) of younger onset 
(age<70) MRI-confirmed lacunar strokes, meaning that although we investigated all 
subtypes, we had most power to identify associations with SVS.  
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In stage II, we took 3 SNPs from the top 25 loci from each phenotype forward for a first in 
silico replication in the NINDS Stroke Genetics Network (SiGN), 2 which consisted of 7,743 
cases and 17,790 controls. We meta-analysed stages I and II together and identified 3 loci 
with p<5x10-7. Finally in stage III, we determine whether these 3 SNPs were associated with 
the phenotype in which they were identified (CE or SVS) by in silico replication in a large 
Icelandic population (deCODE; 520 SVS cases, 1,100 CE cases, 50,728 controls; stage III).  
 
Genotyping and Imputation 
Genotyping, quality control and imputation of all studies has been described previously.2, 3, 13 
All studies were genotyped on commercially available arrays from Illumina or Affymetrix and 
imputed to 1000 Genomes phase 1 reference panels using IMPUTE or MACH.15 Imputation 
quality score was assessed by calculating the ratio of the observed to the expected binomial 
variance of the allele dosage.  
 
Association analysis 
Association analysis was performed using a covariate-informed approach,11, 16 which we, and 
others, have implemented previously.11, 17 Briefly, the approach uses case/control status and 
a covariable – in this case age-at-onset – to estimate each individual’s stroke liability, which 
can be interpreted as their underlying propensity to stroke, on a normally-distributed scale. In 
this analysis cases with an earlier age-at-onset take more extreme positive values than late 
onset cases as, due to the lower prevalence of stroke at younger ages, they are assumed to 
have higher stroke liability. Conversely, controls who are older and stroke-free at age-at-
observation take more extreme negative value than younger controls as they have been 
stroke-free for a longer time and are therefore assumed to have a lower stroke liability. 
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In this analysis, the approach was implemented in our software, CIAO (provided at 
https://sites.google.com/site/mtraylor263/software/covariate-informed-gwas-analysis). 
Specifically, the approach taken is to model phenotype data using a continuous unobserved 
normally distributed quantitative trait, called the disease liability ( = ∑  − 	
 + +
), where  =  + (0,1) and  denotes the genetic effects. Then an individual is a case 
(z=1) if and only if  ≥ 0 and is a control (z=0) otherwise.  is a parameter estimating the 
effect of a given covariate j on the liability scale.  denotes the disease prevalence p at the 
covariate mean 	
 under a normal cumulative distribution function (	Φ(−) = ). This model 
is used to approximate the effect of a disease covariate – in this case age-at-onset - on the 
liability scale, based on estimates of risk of ischaemic stroke by age from epidemiological 
data, thereby estimating . For this analysis, the gender-specific risk of ischaemic stroke by 
age from an index age of 55 was obtained from population-based estimates (1.8%, 5.4%, 
and 12.1% before 65, 75, and 85, respectively in women; 2.4%, 7.3%, and 12.6% before 65, 
75, and 85, respectively in men).18 We assumed that 20% of ischaemic stroke cases had 
each of the cardioembolic, small vessel or large vessel stroke subtypes, approximating 
proportions observed in population-based studies..19 We developed two models for our 
analysis; one based on the risk rates for all ischaemic stroke, and secondly for the three 
stroke subtypes. We used these models to calculate posterior mean liabilities after 
conditioning on age-at-onset for the four stroke phenotypes separately ( (| , ) =
! "#$%(&$&')$( )√+,-
.$/++ 01"
! )√+,-
.$/++ 0#$%(&$&')$( 1"
, 23	 = 1). Controls were modelled in the same way, but were assumed 
to take the posterior mean from the lower (unaffected) portion of the distribution in the 
liability threshold model ((| , ) = ! "
$%(&$&')$(# )√+,-
.$/++ 01"
! )√+,-
.$/++ 0$%(&$&')$(# 1"
, 23	 = 0) . Where age data was 
missing, individuals were assigned the median age value (<1% of cases). Regression was 
then performed on posterior liabilities ((| , )) by multiplying the number of samples by the 
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squared correlation between the expected genotype dosage and posterior mean liabilities for 
each of the discovery cohorts in the four ischaemic stroke phenotypes (all IS, CE, LAS, 
SVS). Ancestry-informative principal components were included where appropriate, using 
the EIGENSTRAT procedure.20 Any residual inflation was accounted for by adjusting results 
by the genomic inflation factor, λ.21 In all analyses, SNPs with imputation quality score<0.7 or 
minor allele frequency<0.01 were excluded and meta-analysis was performed using 
Stouffer’s method in METAL.22 
 
Further analysis of a novel locus associated with small vessel stroke  
For a novel variant associated with SVS, we performed further analysis to elucidate the 
association for different groups based on age-at-onset. Firstly, for datasets in stage I and II, 
we divided the cases into quartiles based on age-at-onset and estimated the association of 
the SNP with each quartile using logistic regression with all controls, meta-analysing using a 
fixed-effects inverse variance weighted approach (data not available in BRAINS, MGH-
GASROS, ISGS/SWISS). Secondly, we interrogated associations at the locus in non-
European ancestry populations, comprising 657 small vessel African-American stroke cases 
and 3,251 matched controls from the NINDS Stroke Genetics Network and African or 
African-Caribbean ancestry individuals from the South London Ethnicity and Stroke Study 
(SLESS), 2, 23 and 314 SVS cases and 5,193 controls of Pakistani ancestry from the RACE 
study.3 We used logistic regression to evaluate the association within each group, and 
evaluated the overall transethnic association by meta-analysing using Stouffer’s method. 
 
In addition, we explored association of the SNP with other SVD phenotypes. We evaluated 
association of the SNP with 1) white matter hyperintensity volumes (WMHV) measured on 
T2-weighted MRI in 3,670 ischaemic stroke patients of European ancestry,24 2) in MRI-
defined small subcortical brain infarcts (SSBI) brain infarcts in 17,197 trans-ethnic individuals 
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(85.7% European; 8.8% African-American; 3.5% Hispanic; 1.0% Chinese; 1.0% Malay) from 
community studies recruited within the neuro-CHARGE consortium (mean age 68.90 ± 
10.31; 1,986 with infarcts). SSBI were defined as MRI-defined brain infarcts of 3-15 mm or 3-
20 mm in size, located in the basal ganglia, the white matter, or the brainstem. Association 
analysis was performed overall, and for the subset of cases with extensive WMH burden – 
defined as the top age-specific quartile of WMH volume on a quantitative scale or above the 
age-specific median by 5-year age-categories for studies using semi-quantitative 
measurements of WMH burden; N=549; 3) ICH in 1,545 European ancestry cases and 1,481 
controls, described previously,25 and stratified according to lobar or nonlobar location.  
 
Evaluation of regulatory chromatin states, mRNA expression and DNA methylation  
To investigate a novel locus, we used existing resources and performed some further 
analyses to characterize its regulatory potential. We interrogated chromatin states and 
regulatory motifs from ENCODE and Epigenomics Roadmap using Haploreg v4.1.26 We also 
evaluated whether the associated SNP influences gene expression using GTEx portal.27 
Upon identifying an association between the SNP and expression of a nearby gene, we 
evaluated the evidence that the association signal for SVS and gene expression derives 
from the same causal variant using a Bayesian colocalisation test.28 Using the R coloc 
package (http://cran.r-project.org/web/packages/coloc), we compared 5 models for SNPs 
with 50Kb of our lead SNP using the approach (H0: No association with either trait; H1: 
Association with SVS, not with expression; H2: Association with expression, not with SVS; 
H3: Association with SVS and expression, two independent SNPs; H4: Association with SVS 
and expression, one shared SNP). 
 
Next, we assessed whether the lead SNP (rs12445022), or 3 SNPs in linkage disequilibrium 
(LD) (rs4843625, rs12920915, rs12444224), influence DNA methylation levels in whole 
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blood. We evaluated genetic associations of whole blood DNA methylation levels at selected 
CpG-sites profiled on the Illumina Infinium HumanMethylation450 BeadChip array in a group 
of 660 monozygotic (MZ) female twins (mean age 59, age range 18 to 79).  These 
individuals were research volunteers from the TwinsUK cohort in the United Kingdom.29 All 
were of European ancestry. For each CpG-site of interest we calculated the normalised 
methylation means for the 330 MZ twin pairs as a phenotype in the genetic analysis, and 
took into account covariates including smoking, BMI, age, methylation plate, and blood cell 
count estimates. TwinsUK imputed genotypes were obtained for the 1000 genomes 
reference set,30 where we excluded SNPs with Hardy–Weinberg p<1x10-4, Minor allele 
frequency (MAF) <5% and those with IMPUTE info value <0.8. We tested for association 
with our SNP, or SNPs in close LD (r2>0.6) with DNA methylation at CpG-sites. We used 
p<4x10-5, equivalent to a false discovery rate (FDR) <5%,31 to identify significant cis-mQTL 
associations. 
 
Finally, we explored genetic associations at 16q24.2 (defined as within 50Kb of rs12445022) 
with DNA methylation profiles in 166 human fetal brain samples (92 male, 74 female) 
ranging from 56–166 days post-conception initially using publically available data – which 
holds results for mQTL associations reaching the study-wide significance threshold 
(http://epigenetics.essex.ac.uk/mQTL/). Methods for this study have been published in detail 
elsewhere.32 Briefly, DNA methylation levels were profiled on the Illumina Infinium 
HumanMethylation450 BeadChip array and SNP genotypes were obtained from the Illumina 
HumanOmniExpress BeadChip and imputed to 1000 Genomes phase 3 using SHAPEIT and 
Minimac3 via the Michigan Imputation Server.15, 33 SNP-methylation probe pairs were tested 
using the R package MatrixEQTL,34 including covariates to control for age, sex and ancestry-
informative principal components. Upon identifying a significant association at 16q24.2, we 
performed additional analyses (not publicly available: we gained access to the data) to test 
whether any of our 4 SNPs (rs12445022, rs4843625, rs12920915, rs12444224) were 
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associated with methylation at the identified probe. We again used p<4x10-5, equivalent to a 
false discovery rate (FDR) <5%,31 to identify significant cis-mQTL associations. 
 
Results 
Association analysis 
In phase I association analysis we confirmed previous associations between HDAC9 and 
LAS (rs2107595, p=3.0x10-8) and between PITX2 and CE (rs192172299, p=2.0x10-9).3, 4 
Previous associations between ZFHX3 and CE and between MMP12 and LAS did not reach 
genome-wide significance in this analysis (rs879324, p=5.0x10-7 and rs586701, p=0.0014; 
respectively).11 A SNP in a region close to HABP2 previously associated with young onset 
ischaemic stroke was also significant, albeit not genome-wide, in this analysis (rs11196288; 
p=2.4x10-4).35 Genomic inflation λ and the equivalent values scaled to 1000 cases and 1000 
controls (λ1000),36 were well controlled across all analyses (IS, λ (λ1000) =1.05 (1.00); CE, λ (λ-
1000) =1.02 (1.00); LAS, λ (λ1000) =1.02 (1.00); SVS. λ (λ1000) =1.01 (1.00)). 
 
We took 25 independent loci forward (3 SNPs in LD from each locus selected on p-value) 
from each analysis (IS, CE, LAS, SVS) for in silico replication in the NINDS Stroke Genetics 
Network study (stage II). Information on these SNPs is provided in Supplementary Tables 1-
4. Following this analysis , excluding previously reported associations, three loci showed 
significance at p<5x10-7 (two with SVS, one with CE) and one was genome-wide significant 
(rs12445022, p=4.4x10-8, associated with SVS). We followed up all three loci in a second in 
silico replication (stage III) in a large Icelandic population (deCODE). A single SNP, 
rs12445022, showed evidence of replication (p=0.011). When performing a meta-analysis 
across all populations, rs12445022 was associated with SVS at genome-wide significance 
(p=3.2x10-9; Figure 2). The SNP was either genotyped or well imputed (info>0.9) in all 
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cohorts and lies in an intergenic region between Junctophilin 3 (JPH3) and Zinc Finger, 
CCHC Domain Containing 14 (ZCCHC14). To confirm the association with rs12445022, we 
repeated the analysis using logistic regression; the approach taken in a conventional GWAS. 
The association was validated using this method, and associations were consistent across 
populations (OR(95% CI)=1.16(1.10-1.22); p=1.3x10-8; heterogeneity p=0.56; Figure 3). 
 
Further analysis of a 16q24.2 novel locus associated with small vessel stroke  
We evaluated association of the lead SNP in different quantiles of age at stroke onset, using 
all controls in each analysis. The strongest associations were observed in younger onset 
cases, suggesting the influence of the SNP might be greatest in these individuals (Figure 4). 
However, this was not demonstrated statistically (p>0.05).  
 
We performed further analysis to assess whether the SVS-associated SNP influenced other 
manifestations of cerebral SVD. The SNP (rs12445022) was also associated with increased 
T2-WMHV (OR(95% CI)=1.10(1.05-1.16); p=5.3x10-5; Figures 2,5), and showed little 
heterogeneity across study groups (heterogeneity p=0.58). Conversely, the SNP was not 
associated with ICH – neither overall, nor in subgroups divided by lobar/non-lobar location. 
For SSBI, the direction of effect was the same as for SVS, but the effect was weaker and 
non-significant (OR(95% CI)=1.05(0.97-1.14); p=0.28). For the subgroup with WMH, the 
effect was stronger – and similar to that observed for SVS, but was again non-significant 
(OR(95% CI)=1.15(0.99-1.33); p=0.076).  
 
We next evaluated the identified locus in non-European ancestry populations. The SNP had 
a similar frequency to Europeans in South Asians from RACE (MAF=37%), but was rarer in 
African ancestry populations, consisting of African-Americans from NINDS Stroke Genetics 
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Network and United Kingdom individuals of African or African-Caribbean ethnicity from 
SLESS (MAF=14%). Associations with the SNP were in the same direction as in European 
ancestry populations (Figure 4), but did not reach statistical significance in either ancestry, 
reflecting the much smaller sample sizes. However, when combining data from all 
populations, evidence for association at the SNP (p=1.4x10-9) was stronger than in 
European ancestry populations alone, which might suggest a common association across 
populations. Indeed, there was not evidence of a significant difference in the strength of 
association between the European and non-European ancestry individuals (p=0.64). 
 
Regulatory chromatin states, mRNA expression and DNA methylation related to 16q24.2 
We used existing databases to assess the functional consequences of SNPs in the 16q24.2 
region. Firstly, we used the Haploreg v4.1 database to interrogate chromatin states and 
regulatory motifs from ENCODE and NIH Roadmap Epigenomics Mapping Consortium. 26, 37, 
38
 The database showed that our lead SNP influences chromatin states in multiple tissues. 
The SNP is classified as a genic promoter in 9 tissues, an enhancer in 13 tissues and 
overlaps DNAse1 hypersensitivity sites in 21 tissues.  
 
Secondly, we used publicly available databases to evaluate the evidence that the lead SNP 
influences expression of nearby genes using the GTEx portal.27 The implicated A allele of 
our lead SNP (rs12445022) was associated with decreased expression of ZCCHC14 in tibial 
arterial tissue (p=9.4x10-7; Figure 2). We used a Bayesian colocalisation technique to assess 
whether the same variant drives the both the SVS association signal and mRNA expression 
of ZCCHC14.28 There was overwhelming evidence in support of H4 (Posterior probability = 
99.7%), strongly indicating that a single variant - most likely to be rs12445022 - influences 
both SVS and expression of ZCCHC14.  
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Finally, we performed analyses to assess whether the lead SNP, or the 3 SNPs in LD, 
influence DNA methylation at CpG probes in whole blood. We found evidence that the lead 
SNP, and 3 SNPs in close LD (r2>0.6), influence DNA methylation at 4 nearby CpG sites 
(cg16596957, cg10312981, cg03020503, cg00555085; all p<4.0x10-5, Table 2). The 
implicated A allele of rs12445022 was associated with decreased methylation at the 
cg16596957 probe (beta(SE)=-0.38(0.082); p=5.3x10-6). The SNPs explained between 5-8% 
of the methylation variance at the given CpG sites. The same 16q24.2 region by CpG probe 
(cg16596957) association was also recently reported in another study in whole blood.40 In 
addition, we looked for an association between SNPs at the 16q24.2 locus and DNA 
methylation levels in fetal brains, initially using publicly available data 
(http://epigenetics.essex.ac.uk/mQTL/). There was a strong association with SNPs in distant 
LD with our lead SNP (rs8047314 ~ cg08031982; p=7.1x10-14; r2=0.16 with rs12445022). We 
then performed additional analyses (not publicly available: we gained access to the data) to 
test if our lead SNP, or the SNPs in close LD, were associated with methylation at 
cg08031982. We could identify no associations that reached our significance threshold 
(p<4.0x10-5). However, there was a near-significant association of rs12920915 and 
rs4843625 with methylation at the cg08031982 probe (both p=7.8x10-5). Our lead SNP, 
rs12445022 was not associated (p=9.9x10-4). 
 
Discussion 
Genome-wide association studies in SVS have largely been disappointing. Some studies 
have suggested that an association with all IS at the highly pleiotropic 12q24.12 is driven by 
an association with SVS, 2 but no genome-wide significant associations specifically with SVS 
have yet been identified. Using an age-of–onset informed analysis approach we identified a 
novel locus at 16q24.2 associated with SVS. The SNP was also associated using a standard 
logistic regression approach, but was less significant – a difference of almost an order of 
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magnitude (p=3.2x10-9 compared to p=1.3x10-8). In addition, the association was stronger 
with younger onset SVS, suggesting a greater influence in these individuals. We tested 
whether the 16q24.2 association extends to other cerebral SVD related phenotypes. We 
showed that the same locus also influences WMH, and may have a similar effect on MRI-
defined subcortical brain infarcts from prospective studies, although the association did not 
reach significance in our analysis. However, the locus does not appear to influence risk of 
ICH. A SNP in the same 16q24.2 region (rs4081947), in partial LD with our SNP (r2=0.28), 
was also recently reported to be associated with migraine in a large GWAS meta-analysis. 41 
These data provide strong supportive evidence that this 16q24.2 locus harbours variants that 
influence diseases of the cerebral vasculature.  
 
Identifying the mechanisms by which GWAS associations influence disease risk presents 
additional challenges. In this case, the underlying mechanism and the specific genes 
implicated remains uncertain. Interrogation of mRNA expression data points to the lead SNP 
influencing expression of the nearest gene, ZCCHC14. This gene is ubiquitously expressed, 
but is highly expressed in arterial tissues and in the brain. However, its function is not well 
characterized. Zinc fingers of the CCHC-type contain an 18 digit residue found in the 
nucleocapsid of retroviruses, and therefore may be important in viral response. Other 
plausible candidate genes reside nearby. The locus lies around 1Mb away from genes 
encoding forkhead box proteins including FOXC2, FOXL1, and FOXF1. These proteins, 
particularly the closely related FOXC1 – a paralogue of FOXC2, have been implicated in 
Mendelian forms of SVS.42 We found no evidence linking our SNP to expression of these 
genes. However, the function of these proteins changes dramatically between early 
development and in adult tissues,43 which might explain the absence of an association. This, 
coupled with the fact that FOXF2 variants have also recently been implicated in ischaemic 
stroke,44 make forkhead box proteins exciting targets for follow-up experiments. 
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Assessing DNA methylation, the process by which methyl groups are added to DNA thereby 
modifying its function, offers another potential method for mechanistic insight. This 
epigenetic process influences gene expression and regulation in humans, and may be 
particularly relevant for diseases such as stroke where gene-environment interactions are 
likely play an important role in pathogenesis.45 Substantial inter-individual variation exists 
with respect to age and tissue type.46 However, an important emerging mechanism 
influencing methylation is local sequence content.47 Notably, recent studies have shown that 
GWAS findings from stroke-relevant traits such as blood pressure are likely to act by 
influencing DNA methylation.48 This may be particularly relevant for SVS, in which 
environmental and other vascular risk factors such as hypertension are important and have 
been shown to interact with disease risk.49 We evaluated whether our associated SNP 
(rs12445022), or SNPs in close LD, influence methylation of nearby CpG sites. We found 
evidence from whole blood that the same genetic variation influences DNA methylation. 
SNPs in distant LD also influenced DNA methylation at a different probe (cg08031982) in the 
fetal brain. Further evidence comes from published studies in lung, breast, and kidney 
tissues,31 as well as in utero,50 all of which have shown that the genetic variation at the same 
16q24.2 region influences methylation at the cg08031982 probe. Interestingly, the CpG sites 
influenced by the locus appear to differ by tissue, with different probes affected in whole 
blood compared to fetal brain. This might imply tissue-specific functional consequences of 
the locus and therefore highlights the importance of performing follow-up experiments in 
appropriate tissues. Based on the evidence presented here, we can only speculate on how 
genetic variation at the locus leads to increased risk of SVS. One hypothesis is that 
expression of ZCCHC14, or other proteins, is mediated through altered methylation of the 
probes identified. This might occur, in part, in response to environmental stimuli. Evaluating 
these hypotheses in a relevant tissue type will be an important future analysis to identify the 
causal mechanisms leading to SVS.  
 
This article is protected by copyright. All rights reserved.
 21
This study has limitations. Our results suggested that the association may be present in 
other ethnicities, but we had an insufficient number of cases to establish common risk 
conclusively. Follow-up studies are therefore required in other ethnic groups. In addition, 
downstream functional experiments will be required to determine the consequences of the 
identified association. The mRNA expression and methylation analyses presented herein 
were constrained by available tissue types. Validation of the findings in more disease 
relevant tissue types such as cerebral small vessels therefore represent important follow-up 
analyses, although obtaining such tissue in a state to allow mRNA studies is very 
challenging. We performed mRNA expression and methylation analyses using either the 
lead SNP (rs12445022) or 3 LD SNPs. The results should be interpreted with the limitation 
that we cannot be certain that any of these SNPs is the causal variant. Radiological 
confirmation of SVS in this study was performed using either CT or MRI. Evidence shows 
that MRI is considerably more reliable at identifying SVS. Replication of the association in an 
MRI-confirmed population may therefore provide a more accurate estimate of the effect of 
the locus on SVS risk. Similarly, interrogation of causative classification system (CCS) 
definitions of SVS may provide further insights. 51 Another method of interrogating the 
combined influence of age and genotype is by testing for an interaction. In this analysis, we 
were unable to do this as age was not available in some sets of controls (e.g WTCCC2). 
 
In this large genome-wide meta-analysis using an age-at-onset informed approach, we have 
identified the first genome-wide significant locus that is associated solely with SVS. Our 
findings, which point to subtle changes in gene expression and DNA methylation influencing 
disease risk, show that strategies that account for different liability across disease related 
covariates such as age can identify novel associations with disease.   
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Table 1 – Ischaemic Stroke Study part ic ipants 
Population IS CE LAS SVS Controls % cases 
with MRI 
Age of cases 
(mean(s.d)) 
Stage I Populations 
ASGC 1,162 240 421 310 1,244 43.0% 72.9 (13.2) 
WTCCC2-Germany 1,174 330 346 106 797 83.0% 66.7 (12.9) 
WTCCC2-UK 2,374 474 498 460 5,175 37.2% 72.2 (12.5) 
Milano 366 64 73 25 407 86.7% 57.4 (15.6) 
DNA-lacunar / GENESIS 1,287 80 64 1,012 970 100.0% 59.6 (12.0) 
LSS 455 157 70 55 455 89.0% 67.7 (14.5) 
ISGS / SWISS 1,014 235 217 187 1,370 83.0% 66.5 (13.6) 
BRAINS 361 29 120 97 444 30.8% 74.4 (14.2) 
MGH-GASROS 294 106 68 23 376 60.0% 66.7 (14.5) 
VISP 1,723 - - - 1,047 47.0% 68.0 (10.7) 
Total (discovery) 10,210 1,715 1,877 2,275 12,285   
Stage II populations 
NINDS Stroke Genetics 
Network 7,743 2,001 1,130 1,408 17,970 62.0% 66.3 (14.8) 
Stage III populations 
deCODE - 1,100 - 520 20,473 NA 72.7 (11.6) 
TOTAL 17,953 4,816 3,007 4,203 50,728   
 
IS, all ischaemic stroke; CE, cardioembolic stroke; LAS, large artery stroke; SVS, small 
vessel stroke; ASGC, Australian Stroke Genetics Collaborative; WTCCC2, Wellcome Trust 
Case Control Consortium 2; LSS, Leuven Stroke Study; BRAINS, Bio-repository of DNA in 
stroke; MGH-GASROS, The MGH Genes Affecting Stroke Risk and Outcome Study; VISP, 
The Vitamin Intervention for Stroke Prevention Trial; NA, information not available. 
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Table 2 – Signif icant associations between rs12445022 and LD SNPs 
(r2>0.6) with c is-methylat ion probes in whole blood 
 
SNP Variant SNP BP CpG Probe Probe BP RA beta (SE) R2 P-value 
rs12445022 87,575,332 cg16596957 87,575,151 A -0.38 (0.082) 0.058 5.3x10-6 
rs4843625 87,576,996 cg16596957 87,575,151 C -0.33 (0.075) 0.053 1.3x10-5 
rs4843625 87,576,996 cg10312981 87,577,304 C 0.39 (0.074) 0.077 1.9x10-7 
rs4843625 87,576,996 cg03020503 87,577,656 C 0.35 (0.075) 0.059 5.0x10-6 
rs4843625 87,576,996 cg00555085 87,616,248 C 0.34 (0.075) 0.057 6.6x10-6 
rs12920915 87,577,521 cg16596957 87,575,151 T -0.38 (0.075) 0.069 7.3x10-7 
rs12920915 87,577,521 cg10312981 87,577,304 T 0.38 (0.075) 0.068 1.0x10-6 
rs12920915 87,577,521 cg03020503 87,577,656 T 0.34 (0.076) 0.055 1.1x10-5 
rs12920915 87,577,521 cg00555085 87,616,248 T 0.33 (0.076) 0.051 2.2x10-5 
rs12444224 87,580,855 cg16596957 87,575,151 T -0.38 (0.075) 0.068 8.0x10-7 
rs12444224 87,580,855 cg10312981 87,577,304 T 0.38 (0.075) 0.069 8.7x10-7 
rs12444224 87,580,855 cg03020503 87,577,656 T 0.35 (0.076) 0.054 1.1x10-5 
rs12444224 87,580,855 cg00555085 87,616,248 T 0.32 (0.076) 0.050 2.6x10-5 
BP, base posi tion; RA, reference al lele; R2 ,  proportion of  methylation 
variance expla ined by respective genotype.  
This article is protected by copyright. All rights reserved.
 26
Figure Legends 
Figure 1 – Flow chart of  analyses performed 
Figure 2 – Associat ions at 16q24.2 wi th A) small  vessel stroke, B) cerebral 
white matter hyperintensit ies, C)  mRNA expression of  ZCCHC14; and D) 
Gene Locations and associat ions of  the locus with DNA methylat ion 
SVS, small vessel stroke; WMH, white matter hyperintensities; ZCCHC14, Zinc Finger, 
CCHC Domain Containing 14; JPH3, Junctophilin 3; meQTL, methylation quantitative trait 
locus. 
Figure 3 – Forest Plot of  Associat ions with rs12445022 under a logistic  
regression model 
 
Figure 4 – Association of  rs12445022 with small vessel stroke by quart i les of  
age-at-stroke onset in Europeans 
 
Figure 5 – Associat ions with rs12445022 for stroke and cerebral  small  vessel 
disease phenotypes 
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Figure 1 – Flow chart of analyses performed  
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Figure 2 – Associations at 16q24.2 with A) small vessel stroke, B) cerebral white matter hyperintensities, C) 
mRNA expression of ZCCHC14; and D) Gene Locations and associations of the locus with DNA methylation  
SVS, small vessel stroke; WMH, white matter hyperintensities; ZCCHC14, Zinc Finger, CCHC Domain 
Containing 14; JPH3, Junctophilin 3; meQTL, methylation quantitative trait locus.  
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Figure 3 – Forest Plot of Associations with rs12445022 under a logistic regression model  
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Figure 4 – Association of rs12445022 with small vessel stroke by quartiles of age-at-stroke onset in 
Europeans  
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Figure 5 – Associations with rs12445022 for stroke and cerebral small vessel disease phenotypes  
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Supplementary Table 1 – Small Vessel Stroke association statistics for SNPs taken forward to Stage II 
        Stage I         Stage II & III     Overall   
SNP CHR BP Allele1 Allele2 Freq1 Zscore P.value Freq1 Zscore P.value Freq1 Zscore P.value 
rs12445022 16 87575332 a g 0.3378 4.813 1.49E-06 0.3233 3.981 6.87E-05 0.3273 5.923 3.17E-09 
rs12920915 16 87577521 t c 0.4041 4.255 2.10E-05 0.3999 3.353 0.0007993 0.4018 5.337 9.44E-08 
rs17879928 1 92160300 a g 0.7982 4.603 4.17E-06 0.7951 2.430 0.01509 0.7897 4.495 6.95E-07 
rs11807260 1 92160761 a g 0.2019 -4.595 4.32E-06 0.2051 -2.238 0.00466 0.2037 -5.175 2.27E-07 
rs12444224 16 87580855 t c 0.4035 4.149 3.34E-05 0.4008 3.224 0.001266 0.402 5.17 2.34E-07 
rs6693438 1 92163174 a g 0.7978 4.583 4.58E-06 0.794 2.151 0.006036 0.7957 5.105 3.31E-07 
rs1961463 10 3506218 a g 0.2904 -4.651 3.30E-06 0.2891 -2.356 0.01848 0.2897 -4.86 1.17E-06 
rs2053889 10 3509300 t g 0.2922 -4.42 9.89E-06 0.2902 -2.524 0.0116 0.2911 -4.83 1.36E-06 
rs8073136 17 52654201 t c 0.7574 -4.285 1.83E-05 0.7576 -2.594 0.0095 0.7575 -4.792 1.65E-06 
rs7225084 17 52652493 t g 0.7585 -4.266 1.99E-05 0.759 -2.513 0.01199 0.7588 -4.719 2.37E-06 
rs115936795 17 2572778 t g 0.0158 4.481 7.44E-06 0.0149 2.354 0.01856 0.0153 4.68 2.86E-06 
rs12244869 10 3499052 c g 0.7037 4.529 5.94E-06 0.7032 2.184 0.02894 0.7034 4.651 3.31E-06 
rs138515134 17 2579590 t g 0.9852 -4.501 6.77E-06 0.9856 -2.276 0.02284 0.9854 -4.633 3.60E-06 
rs2439998 17 2537551 t c 0.0189 4.47 7.81E-06 0.0181 2.188 0.02864 0.0185 4.599 4.24E-06 
rs73519263 16 27123478 t g 0.9822 -4.714 2.42E-06 0.9795 -2.085 0.03709 0.9805 -4.5 6.79E-06 
rs73519272 16 27124978 t g 0.0178 4.657 3.21E-06 0.0206 2.056 0.03983 0.0196 4.442 8.90E-06 
rs896644 18 59247445 a t 0.9107 -4.564 5.01E-06 0.9107 -1.801 0.07176 0.9107 -4.389 1.14E-05 
rs1452583 18 59241941 a t 0.0883 4.555 5.24E-06 0.0893 1.751 0.07989 0.0889 4.346 1.39E-05 
rs148398060 16 27105221 a g 0.017 4.494 7.01E-06 0.0202 1.803 0.07147 0.0189 4.24 2.24E-05 
rs9827208 3 7908121 a g 0.688 -5.102 3.36E-07 0.6925 -1.1 0.2713 0.6905 -4.227 2.37E-05 
rs6567220 18 59241643 a g 0.9098 -4.665 3.08E-06 0.9076 -1.475 0.1401 0.9086 -4.214 2.51E-05 
rs2083833 17 52655010 t c 0.192 4.353 1.35E-05 0.1892 1.742 0.08143 0.1904 4.204 2.62E-05 
rs7615995 3 7923100 a t 0.3109 5.048 4.46E-07 0.3085 1.117 0.2641 0.3096 4.203 2.63E-05 
rs13386661 2 59883352 t c 0.0196 4.61 4.03E-06 0.0189 1.528 0.1265 0.0192 4.153 3.29E-05 
rs72952365 2 59859190 t c 0.0162 4.212 2.53E-05 0.0182 1.744 0.08115 0.0174 4.059 4.93E-05 
rs6737557 2 59885842 t c 0.9834 -4.177 2.95E-05 0.981 -1.693 0.09036 0.982 -3.998 6.39E-05 
rs17076342 3 44079629 a g 0.8959 -4.171 3.03E-05 0.9035 -1.185 0.2361 0.9001 -3.668 0.0002445 
rs9871447 3 44079944 t c 0.103 4.11 3.96E-05 0.0976 1.234 0.2172 0.1 3.663 0.0002489 
rs9817280 3 44083722 a g 0.0986 4.155 3.26E-05 0.0965 1.182 0.2371 0.0974 3.655 0.0002571 
Page 37 of 48
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
rs373151 3 7927037 a g 0.5832 4.992 5.97E-07 0.593 0.421 0.6738 0.5886 3.648 0.0002644 
rs2019441 18 23197880 t c 0.9643 -4.465 8.00E-06 0.9652 -0.647 0.5178 0.9648 -3.464 0.0005324 
rs870399 11 131456204 t c 0.2958 -4.114 3.88E-05 0.2894 -0.902 0.3673 0.2922 -3.403 0.0006656 
rs9356705 6 19677864 t c 0.0358 4.859 1.18E-06 0.0337 0.334 0.7384 0.0346 3.375 0.0007389 
rs73395542 18 23192332 a g 0.9639 -4.336 1.45E-05 0.9649 -0.534 0.593 0.9645 -3.294 0.0009886 
rs4800650 18 23192273 a t 0.9639 -4.334 1.47E-05 0.9649 -0.531 0.5953 0.9645 -3.29 0.001002 
rs2190179 7 79045496 a c 0.265 4.282 1.85E-05 0.273 0.514 0.6069 0.2694 3.243 0.001181 
rs10238315 7 79043013 t g 0.2653 4.279 1.88E-05 0.2729 0.503 0.6152 0.2695 3.232 0.001229 
rs2288131 12 29683089 t c 0.3092 4.347 1.38E-05 0.3124 0.391 0.696 0.311 3.194 0.001401 
rs299456 12 29695861 a g 0.3155 4.246 2.17E-05 0.3198 0.277 0.782 0.3179 3.042 0.002348 
rs299457 12 29696329 t c 0.3156 4.245 2.18E-05 0.3198 0.271 0.7866 0.3179 3.037 0.002388 
rs4730806 7 79030922 a c 0.7351 -4.103 4.08E-05 0.7269 -0.305 0.7601 0.7306 -2.968 0.002998 
rs60475239 2 219047216 a t 0.5464 -4.811 1.50E-06 0.3428 1.062 0.2884 0.4529 -2.819 0.004813 
rs9368108 6 19692570 a t 0.9555 -4.864 1.15E-06 0.9604 0.43 0.6673 0.9584 -2.792 0.005238 
rs72657608 6 19691522 t c 0.0445 4.864 1.15E-06 0.0397 -0.433 0.6647 0.0417 2.789 0.005281 
rs4937638 11 131456484 a t 0.4282 4.219 2.46E-05 0.4153 0.221 0.825 0.4201 2.76 0.005779 
rs12363659 11 131456719 a g 0.5718 -4.211 2.54E-05 0.5847 -0.215 0.8296 0.5799 -2.751 0.005948 
rs12743454 1 208339738 a g 0.6561 4.372 1.23E-05 0.6511 -0.313 0.7544 0.6533 2.687 0.007203 
rs2590685 1 208339232 a g 0.6553 4.316 1.59E-05 0.6493 -0.287 0.7739 0.652 2.669 0.007609 
rs4674267 2 219046437 t c 0.4322 4.894 9.86E-07 0.4468 -1.073 0.2834 0.4403 2.471 0.01348 
rs11894169 2 219046846 t c 0.4332 4.802 1.57E-06 0.4474 -1.075 0.2823 0.4411 2.408 0.01605 
rs13181146 5 176128648 a t 0.8334 4.329 1.50E-05 0.8192 -0.735 0.4622 0.8252 2.247 0.02462 
rs2884531 5 176129392 t c 0.1664 -4.275 1.91E-05 0.1812 0.794 0.4273 0.175 -2.168 0.03018 
rs9515350 13 111668229 a g 0.869 -3.552 0.0003818 0.8635 0.425 0.671 0.866 -2.057 0.03971 
rs139728593 8 99641925 a c 0.0122 4.741 2.13E-06 0.0109 -1.455 0.1456 0.0115 2.023 0.04309 
rs11737790 4 120751664 t c 0.337 4.304 1.68E-05 0.3274 -1.17 0.242 0.3317 2.004 0.04503 
rs4868697 5 176129823 c g 0.8232 4.196 2.72E-05 0.8054 -0.997 0.3186 0.8129 1.962 0.04981 
rs6534157 4 120753056 c g 0.6642 -4.272 1.94E-05 0.6738 1.286 0.1983 0.6695 -1.896 0.05791 
rs6858155 4 120754216 t g 0.3358 4.27 1.96E-05 0.3266 -1.306 0.1917 0.3307 1.88 0.06006 
rs10996826 10 67776227 a g 0.5221 -4.33 1.49E-05 0.5205 1.398 0.1621 0.5212 -1.852 0.06406 
rs10822693 10 67776999 c g 0.478 4.331 1.48E-05 0.4795 -1.4 0.1614 0.4788 1.851 0.06419 
rs189950918 8 99535634 c g 0.0117 4.342 1.41E-05 0.0103 -1.36 0.1737 0.0109 1.832 0.06695 
Page 38 of 48
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
rs7098171 10 67780663 t c 0.5133 -4.437 9.14E-06 0.518 1.527 0.1267 0.5159 -1.827 0.06772 
rs6656221 1 208329618 a g 0.6852 3.907 9.35E-05 0.687 -1.164 0.2443 0.6862 1.743 0.08129 
rs67730808 13 111661710 a g 0.1347 3.307 0.0009441 0.1362 -0.691 0.4899 0.1355 1.695 0.09009 
rs146021580 3 121766140 a c 0.0244 4.355 1.33E-05 0.0235 -1.677 0.09346 0.0239 1.661 0.09672 
rs9515357 13 111683822 t c 0.128 3.426 0.0006122 0.1217 -0.889 0.3738 0.1245 1.627 0.1038 
rs35538837 3 121659202 a g 0.0269 4.188 2.82E-05 0.0262 -1.659 0.09718 0.0265 1.563 0.1181 
rs142283780 22 24334674 t c 0.1523 4.075 4.59E-05 0.1538 -1.161 0.2458 0.1532 1.559 0.1189 
rs118094794 8 99479692 a g 0.9882 -4.039 5.38E-05 0.9898 1.47 0.1415 0.9891 -1.549 0.1213 
rs140004544 3 121689502 t c 0.0281 4.245 2.19E-05 0.0273 -1.761 0.07824 0.0277 1.525 0.1273 
rs4337774 4 67107733 a g 0.0548 4.243 2.21E-05 0.054 -1.633 0.1024 0.0543 1.508 0.1317 
rs11131636 4 67108352 a g 0.0572 4.321 1.55E-05 0.0544 -1.731 0.0834 0.0556 1.484 0.1379 
rs79215719 4 67106740 c g 0.0544 4.288 1.80E-05 0.0523 -1.734 0.08288 0.0532 1.46 0.1442 
rs7291499 22 24341101 a g 0.1545 4.17 3.04E-05 0.1542 -1.395 0.1631 0.1543 1.431 0.1524 
rs182268832 22 24334133 t g 0.1456 4.062 4.88E-05 0.1484 -1.371 0.1705 0.1474 1.384 0.1663 
 
CHR, chromosome; BP, base position; Freq1, frequency of Allele1; Stage III results included for rs12445022 and rs17879928 only 
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Supplementary Table 2 – Large Artery Stroke association statistics for SNPs taken forward to Stage II 
        Stage I         Stage II     Overall   
SNP CHR BP Allele1 Allele2 Freq1 Zscore P.value Freq1 Zscore P.value Freq1 Zscore P.value 
rs71524263 7 19030278 t c 0.1157 5.309 1.10E-07 0.1218 4.769 1.85E-06 0.1194 7.047 1.83E-12 
rs2107595 7 19049388 a g 0.1614 5.541 3.02E-08 0.163 4.19 2.78E-05 0.1623 6.815 9.46E-12 
rs57301765 7 19052733 a g 0.1634 5.502 3.77E-08 0.1669 4.134 3.56E-05 0.1654 6.747 1.51E-11 
rs12939005 17 52986484 t g 0.2018 4.379 1.19E-05 0.1903 2.384 0.01712 0.1954 4.693 2.69E-06 
rs72749603 5 31178840 a c 0.9636 -4.865 1.14E-06 0.9628 -1.943 0.05206 0.9632 -4.687 2.77E-06 
rs72829469 17 52989920 a g 0.2025 4.375 1.22E-05 0.1904 2.352 0.01868 0.1958 4.666 3.07E-06 
rs2332312 17 52996429 a g 0.2033 4.394 1.11E-05 0.1927 2.202 0.02769 0.1974 4.567 4.95E-06 
rs62367577 5 86802658 t g 0.8479 -4.236 2.28E-05 0.8436 -2.299 0.02152 0.8455 -4.534 5.78E-06 
rs7342953 17 63245585 t c 0.0316 4.722 2.33E-06 0.0298 1.83 0.0672 0.0306 4.508 6.54E-06 
rs59192960 5 31181789 t c 0.0385 4.569 4.91E-06 0.0377 1.903 0.05708 0.0381 4.46 8.20E-06 
rs80160193 17 63243822 a t 0.0316 4.642 3.45E-06 0.0299 1.787 0.07395 0.0307 4.422 9.76E-06 
rs76490029 17 63243674 t c 0.0316 4.64 3.48E-06 0.0299 1.787 0.074 0.0307 4.421 9.84E-06 
rs11696561 20 17455185 a g 0.2813 -4.492 7.04E-06 0.2773 -1.577 0.1149 0.2791 -4.166 3.11E-05 
rs4239702 20 44749251 t c 0.2749 4.652 3.29E-06 0.2867 1.423 0.1546 0.2815 4.157 3.22E-05 
rs55862206 4 129591442 c g 0.9211 -4.677 2.91E-06 0.9227 -1.378 0.1681 0.922 -4.14 3.47E-05 
rs56299512 4 129591445 a g 0.9211 -4.677 2.91E-06 0.9227 -1.378 0.1681 0.922 -4.14 3.47E-05 
rs10811652 9 22077085 a c 0.5057 -4.419 9.93E-06 0.4967 -1.567 0.1171 0.5007 -4.109 3.97E-05 
rs72783748 5 86863605 a g 0.7635 -4.319 1.57E-05 0.7485 -1.638 0.1014 0.7551 -4.096 4.20E-05 
rs10757271 9 22076795 a g 0.5051 -4.37 1.24E-05 0.4962 -1.586 0.1128 0.5001 -4.091 4.30E-05 
rs34562050 4 129594713 c g 0.08 4.677 2.91E-06 0.0789 1.224 0.221 0.0794 4.025 5.69E-05 
rs11607832 11 102544684 t c 0.9299 -4.008 6.13E-05 0.9332 -1.761 0.0783 0.9317 -3.981 6.88E-05 
rs9632884 9 22072301 c g 0.4918 4.389 1.14E-05 0.5007 1.241 0.2145 0.4968 3.846 0.00012 
rs11905301 20 24531347 t c 0.4669 4.274 1.92E-05 0.5327 1.404 0.1603 0.5054 3.829 0.0001289 
rs7720392 5 31170385 t c 0.9661 -4.074 4.63E-05 0.9668 -1.451 0.1467 0.9665 -3.793 0.0001486 
rs4810485 20 44747947 t g 0.2506 4.092 4.29E-05 0.2608 1.413 0.1576 0.2563 3.777 0.0001587 
rs12635174 3 117008209 t c 0.7228 4.45 8.60E-06 0.7307 1.08 0.28 0.7272 3.767 0.0001654 
rs11696580 20 17455276 t g 0.1926 -4.222 2.42E-05 0.198 -1.247 0.2122 0.1956 -3.74 0.0001838 
rs1883832 20 44746982 t c 0.2507 4.039 5.38E-05 0.2607 1.405 0.16 0.2563 3.736 0.0001872 
rs74725770 7 93946272 a g 0.989 -4.857 1.19E-06 0.989 -0.903 0.3665 0.989 -3.716 0.0002021 
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rs10049229 3 117001187 a g 0.2775 -4.45 8.58E-06 0.2703 -0.962 0.3359 0.2735 -3.679 0.0002342 
rs6075215 20 17454302 a g 0.1931 -4.225 2.40E-05 0.1983 -1.142 0.2534 0.196 -3.663 0.0002492 
rs13092499 3 117009819 a c 0.7229 4.45 8.58E-06 0.73 0.863 0.388 0.7269 3.605 0.0003122 
rs13039850 20 24547144 t c 0.3574 -4.545 5.51E-06 0.348 -0.646 0.5181 0.3522 -3.506 0.0004554 
rs1561734 5 86826750 a g 0.2109 4.298 1.73E-05 0.2253 0.839 0.4015 0.2189 3.485 0.0004913 
rs75684303 7 93878978 a g 0.011 4.704 2.55E-06 0.008 0.773 0.4398 0.0091 3.442 0.0005773 
rs11159150 14 76162001 a g 0.3084 -4.34 1.43E-05 0.3038 -0.646 0.5185 0.3058 -3.369 0.0007545 
rs1005224 14 76173860 a t 0.6902 4.286 1.82E-05 0.6912 0.683 0.4944 0.6908 3.361 0.0007756 
rs727409 20 24557527 t c 0.3202 -4.252 2.12E-05 0.3164 -0.692 0.4889 0.3181 -3.345 0.0008222 
rs662558 11 102718695 t c 0.8213 -3.524 0.0004255 0.8117 -1.321 0.1865 0.8159 -3.33 0.0008671 
rs2660040 10 68275581 a g 0.294 4.797 1.61E-06 0.2961 0.142 0.8872 0.2952 3.297 0.000978 
rs8073683 17 17555596 t c 0.474 -4.525 6.05E-06 0.4749 -0.327 0.7436 0.4745 -3.254 0.001137 
rs1522966 3 34843726 a t 0.5229 4.594 4.36E-06 0.5211 0.227 0.8206 0.5219 3.225 0.001259 
rs118001792 11 41905979 a c 0.0136 4.391 1.13E-05 0.0143 0.32 0.7492 0.014 3.16 0.00158 
rs586701 11 102724730 t g 0.8236 -3.194 0.001405 0.8134 -1.372 0.1701 0.8179 -3.149 0.001639 
rs61103969 11 41897789 a g 0.0136 4.526 6.00E-06 0.0145 0.174 0.8622 0.0141 3.141 0.001685 
rs525673 3 34848226 t c 0.523 4.636 3.56E-06 0.5227 0.063 0.95 0.5228 3.131 0.001744 
rs7893676 10 68270632 c g 0.2923 4.152 3.30E-05 0.2863 0.483 0.629 0.289 3.123 0.001791 
rs12258032 10 68271859 t c 0.7076 -4.138 3.50E-05 0.7137 -0.485 0.6275 0.711 -3.115 0.001838 
rs1916227 3 34847097 a g 0.4774 -4.58 4.64E-06 0.4776 -0.069 0.9454 0.4775 -3.098 0.001947 
rs11626058 14 76115445 a c 0.3724 -4.253 2.11E-05 0.3734 -0.346 0.7296 0.373 -3.087 0.002021 
rs58980959 11 41903641 c g 0.0136 4.387 1.15E-05 0.0145 0.194 0.8461 0.0141 3.063 0.00219 
rs7164538 15 60155804 a g 0.9679 4.824 1.41E-06 0.9714 -0.337 0.7361 0.9699 2.957 0.003103 
rs7164565 15 60155858 a g 0.9679 4.823 1.41E-06 0.9714 -0.338 0.7356 0.9699 2.957 0.00311 
rs191633333 7 93746175 a c 0.0112 4.804 1.56E-06 0.011 -0.065 0.9484 0.0111 2.872 0.004074 
rs12414028 10 104957629 a t 0.0924 -4.102 4.10E-05 0.0959 -0.181 0.856 0.0944 -2.864 0.004181 
rs2099580 15 60157890 t g 0.9683 4.852 1.22E-06 0.9718 -0.449 0.6535 0.9703 2.861 0.004218 
rs16870743 5 73016810 a g 0.7238 -4.465 8.01E-06 0.7232 0.168 0.8664 0.7235 -2.845 0.004447 
rs644993 11 97541637 a g 0.1229 4.371 1.24E-05 0.1276 -0.138 0.8906 0.1255 2.805 0.005027 
rs79472290 4 156589785 t c 0.0149 4.065 4.80E-05 0.0152 0.384 0.701 0.0151 2.797 0.005153 
rs680900 11 97538429 a g 0.127 4.419 9.91E-06 0.1336 -0.231 0.8176 0.1307 2.768 0.005646 
rs59216006 5 73001469 a g 0.7174 -4.378 1.20E-05 0.7156 0.21 0.8338 0.7164 -2.756 0.005856 
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CHR, chromosome; BP, base position; Freq1, frequency of Allele1 
 
rs17400036 6 69707211 t g 0.9298 -4.285 1.83E-05 0.9294 0.133 0.8939 0.9296 -2.751 0.005944 
rs56120605 6 69714649 a g 0.9299 -4.32 1.56E-05 0.9304 0.174 0.8622 0.9302 -2.744 0.006072 
rs6878052 5 72999965 a g 0.2824 4.371 1.24E-05 0.2842 -0.229 0.8188 0.2834 2.737 0.006202 
rs11191548 10 104846178 t c 0.919 3.734 0.0001888 0.9099 0.297 0.7662 0.9139 2.706 0.006816 
rs9901291 17 17541750 a g 0.4376 4.577 4.73E-06 0.447 -0.482 0.6295 0.4428 2.684 0.007267 
rs597928 11 97545967 a c 0.1251 4.444 8.85E-06 0.1282 -0.375 0.708 0.1268 2.676 0.007442 
rs3740390 10 104638480 t c 0.0841 -3.774 0.0001605 0.092 0.004 0.9965 0.0885 -2.507 0.01216 
rs12972736 19 6656777 t c 0.2588 -4.538 5.67E-06 0.2626 0.702 0.4829 0.261 -2.389 0.01688 
rs12977994 19 6655261 t c 0.2543 -4.307 1.66E-05 0.2564 0.742 0.4579 0.2555 -2.209 0.02717 
rs56111161 1 204695345 t c 0.014 4.945 7.63E-07 0.0133 -1.322 0.1863 0.0136 2.177 0.02946 
rs11240252 1 204691325 a g 0.0143 4.98 6.35E-07 0.0138 -1.703 0.08851 0.014 1.909 0.05632 
rs55878455 6 69639391 t c 0.9259 -3.878 0.0001054 0.9211 0.824 0.4097 0.9231 -1.877 0.06059 
rs3738157 1 204684426 a g 0.0119 4.941 7.76E-07 0.012 -1.653 0.09839 0.012 1.818 0.06912 
rs62066209 17 17520784 t c 0.388 4.531 5.88E-06 0.3868 -1.609 0.1077 0.3873 1.813 0.06984 
rs12608923 19 6659855 a g 0.2464 -4.435 9.22E-06 0.2482 1.191 0.2337 0.2475 -1.724 0.08466 
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Supplementary Table 3 – Cardioembolic Stroke association statistics for SNPs taken forward to Stage II 
        Stage I         Stage II & III   Overall   
SNP CHR BP Allele1 Allele2 Freq1 Zscore P.value Freq1 Zscore P.value Freq1 Zscore P.value 
rs192172299 4 111681501 t g 0.2148 5.994 2.05E-09 0.2217 6.832 8.39E-12 0.2187 9.088 1.01E-19 
rs2466455 4 111685615 t c 0.7979 -5.725 1.04E-08 0.7763 -7.052 1.76E-12 0.7858 -9.076 1.13E-19 
rs2634074 4 111677041 a t 0.7975 -5.739 9.55E-09 0.7759 -7.018 2.25E-12 0.7854 -9.059 1.32E-19 
rs879324 16 73068678 a g 0.1721 5.026 5.02E-07 0.1681 3.371 0.0007501 0.1699 5.853 4.83E-09 
rs12932445 16 73069888 t c 0.8278 -4.866 1.14E-06 0.8313 -3.293 0.0009929 0.8298 -5.689 1.28E-08 
rs4499262 16 73059159 a c 0.168 4.893 9.94E-07 0.165 3.043 0.002345 0.1663 5.519 3.40E-08 
rs8134198 21 45369535 t g 0.3246 4.717 2.40E-06 0.3302 2.308 0.02102 0.3335 4.402 1.07E-05 
rs139223992 5 31110574 t c 0.9116 -4.593 4.37E-06 0.9115 -2.319 0.02037 0.9115 -4.779 1.77E-06 
rs72747745 5 31111931 a g 0.0879 4.498 6.87E-06 0.088 2.372 0.01771 0.088 4.755 1.99E-06 
rs183560286 6 105692807 a g 0.0769 4.254 2.10E-05 0.0719 2.64 0.008287 0.0739 4.721 2.35E-06 
rs4941428 13 43008177 a g 0.2564 4.269 1.96E-05 0.2494 2.52 0.01172 0.2525 4.715 2.42E-06 
rs11740741 5 31114581 t c 0.0897 4.573 4.81E-06 0.0888 2.198 0.02792 0.0892 4.675 2.94E-06 
rs7100632 10 134653951 t c 0.5884 -4.463 8.08E-06 0.6015 -2.287 0.02218 0.5958 -4.669 3.03E-06 
rs17065682 6 105704149 t g 0.9235 -4.091 4.29E-05 0.9269 -2.683 0.007303 0.9256 -4.653 3.28E-06 
rs17065694 6 105704658 t c 0.0766 4.101 4.11E-05 0.073 2.648 0.008106 0.0744 4.631 3.63E-06 
rs3750580 10 134650440 t c 0.6018 -4.296 1.74E-05 0.6147 -2.367 0.01794 0.609 -4.618 3.88E-06 
rs4880434 10 134648569 a g 0.5867 -4.424 9.69E-06 0.6007 -2.155 0.03113 0.5946 -4.544 5.52E-06 
rs2147160 13 43021639 a c 0.7445 -4.036 5.43E-05 0.7516 -2.491 0.01275 0.7485 -4.539 5.66E-06 
rs1351832 13 43057549 t c 0.255 4.064 4.82E-05 0.2483 2.417 0.01564 0.2512 4.502 6.73E-06 
rs11868827 17 69773732 t c 0.1269 -4.4 1.08E-05 0.1239 -1.94 0.05237 0.1252 -4.367 1.26E-05 
rs552148 9 136153481 t c 0.2482 -4.133 3.59E-05 0.2414 -2.126 0.03353 0.2444 -4.329 1.50E-05 
rs663367 9 136153451 a g 0.2481 -4.125 3.71E-05 0.2413 -2.117 0.03428 0.2443 -4.317 1.58E-05 
rs12453161 17 69752498 a g 0.1291 -4.431 9.36E-06 0.1252 -1.84 0.06581 0.1269 -4.312 1.62E-05 
rs500428 9 136155343 a g 0.2483 -4.115 3.88E-05 0.2415 -2.11 0.03483 0.2445 -4.305 1.67E-05 
rs1953522 1 216837241 a c 0.3773 -4.493 7.04E-06 0.3647 -1.697 0.08962 0.3702 -4.246 2.18E-05 
rs7252834 19 16075211 a g 0.7727 -4.205 2.61E-05 0.7502 -1.774 0.07608 0.7601 -4.113 3.90E-05 
rs73226947 21 45363522 t g 0.3552 3.848 0.0001189 0.3598 2.042 0.04116 0.3578 4.065 4.79E-05 
rs2838444 21 45360862 a g 0.3507 3.898 9.70E-05 0.3525 1.982 0.04745 0.3517 4.053 5.06E-05 
rs7252929 19 16075678 t c 0.2274 4.257 2.07E-05 0.2493 1.627 0.1037 0.2397 4.038 5.40E-05 
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rs1594692 19 16075015 t c 0.7724 -4.182 2.90E-05 0.7495 -1.673 0.09437 0.7595 -4.022 5.78E-05 
rs10958962 9 10229902 t c 0.7405 -4.381 1.18E-05 0.7464 -1.451 0.1469 0.7438 -3.987 6.69E-05 
rs2429937 17 69717560 a g 0.1482 -4.397 1.10E-05 0.1462 -1.356 0.1752 0.1471 -3.927 8.62E-05 
rs922982 9 84348195 c g 0.4474 4.319 1.57E-05 0.4505 1.342 0.1796 0.4491 3.865 0.0001112 
rs4434691 9 84348762 a c 0.4475 4.304 1.67E-05 0.4505 1.344 0.1788 0.4492 3.857 0.0001148 
rs7380303 5 168722937 t c 0.7424 -5.203 1.96E-07 0.7314 -0.406 0.685 0.7362 -3.748 0.0001783 
rs4242184 5 168726086 a g 0.7436 -5.09 3.58E-07 0.7328 -0.466 0.6415 0.7375 -3.718 0.0002007 
rs1455181 9 3774843 a c 0.4018 4.726 2.29E-06 0.4009 0.712 0.4767 0.4013 3.661 0.0002509 
rs10061289 5 168718340 c g 0.7666 -5.142 2.71E-07 0.7587 -0.337 0.7362 0.7622 -3.656 0.0002559 
rs80129168 5 56481753 a g 0.1082 -4.049 5.14E-05 0.1057 -1.227 0.2198 0.1068 -3.583 0.0003403 
rs1997571 7 116198621 a g 0.5916 4.2 2.67E-05 0.5846 1.033 0.3016 0.5877 3.554 0.0003789 
rs1997572 7 116198828 a g 0.4084 -4.2 2.67E-05 0.4154 -1.033 0.3017 0.4123 -3.554 0.0003794 
rs10867804 9 84341050 a c 0.4322 4.326 1.52E-05 0.4379 0.903 0.3666 0.4354 3.54 0.0003999 
rs13361596 5 56540855 t c 0.1088 -4.007 6.15E-05 0.1078 -1.207 0.2272 0.1082 -3.54 4.00E-04 
rs3807989 7 116186241 a g 0.4068 -4.09 4.32E-05 0.4149 -1.064 0.2875 0.4114 -3.504 0.0004579 
rs2065070 9 10222790 c g 0.7354 -4.117 3.83E-05 0.7412 -0.986 0.3239 0.7387 -3.465 0.0005308 
rs12698965 7 70441601 t c 0.6205 4.433 9.31E-06 0.6186 1.009 0.3128 0.6193 3.461 0.0005382 
rs3786778 19 48285809 t c 0.9559 -4.468 7.90E-06 0.9508 -0.661 0.5088 0.953 -3.453 0.0005551 
rs12983568 19 48272855 t c 0.9551 -4.495 6.96E-06 0.9528 -0.63 0.5284 0.9538 -3.448 0.0005651 
rs10269258 7 70440091 t c 0.3795 -4.438 9.06E-06 0.3817 -0.982 0.326 0.3809 -3.443 0.0005758 
rs6460609 7 70437060 t c 0.6203 4.394 1.11E-05 0.6182 0.965 0.3344 0.619 3.403 0.0006674 
rs10471998 5 56447742 a g 0.8859 4.458 8.26E-06 0.8908 0.911 0.3621 0.8891 3.366 0.0007637 
rs75781828 3 6994624 t c 0.1182 -4.347 1.38E-05 0.1123 -0.548 0.5837 0.1149 -3.288 0.001008 
rs12973532 19 48264879 a g 0.9346 -4.432 9.36E-06 0.9295 -0.454 0.6501 0.9317 -3.273 0.001063 
rs11071630 15 62098001 t c 0.3935 4.466 7.98E-06 0.3968 0.421 0.6736 0.3954 3.272 0.001069 
rs10809038 9 10229301 t c 0.8813 -3.966 7.32E-05 0.8788 -0.83 0.4067 0.8799 -3.247 0.001167 
rs1472433 10 4661676 a g 0.2765 4.461 8.18E-06 0.2749 0.388 0.6982 0.2756 3.243 0.001182 
rs10973456 9 3774359 t c 0.5761 -4.452 8.52E-06 0.5761 -0.367 0.7139 0.5761 -3.222 0.001275 
rs7910959 10 4646222 a t 0.2755 4.466 7.97E-06 0.2743 0.354 0.7232 0.2748 3.222 0.001275 
rs149397829 3 6991641 t c 0.1161 -4.267 1.98E-05 0.1121 -0.521 0.6021 0.1139 -3.215 0.001303 
rs1021632 10 4652819 t g 0.2764 4.451 8.54E-06 0.2753 0.357 0.721 0.2758 3.214 0.001309 
rs116972146 13 69632241 t c 0.9641 -4.219 2.46E-05 0.9659 -0.562 0.5743 0.9651 -3.214 0.001311 
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CHR, chromosome; BP, base position; Freq1, frequency of Allele1; Stage III results included for rs8134198 only 
 
rs13379934 15 62096931 a t 0.7639 -3.906 9.37E-05 0.7501 -0.771 0.441 0.7561 -3.163 0.00156 
rs181957491 13 69635572 a g 0.9672 -4.11 3.95E-05 0.9682 -0.543 0.5869 0.9678 -3.128 0.00176 
rs2163735 3 6995426 a g 0.116 -4.171 3.04E-05 0.1117 -0.434 0.6643 0.1136 -3.086 0.00203 
rs1268153 6 109035696 a g 0.0324 4.286 1.82E-05 0.0319 0.512 0.6086 0.0321 3.081 0.002062 
rs34716044 15 62097134 t g 0.762 -3.767 0.0001655 0.7487 -0.729 0.4658 0.7545 -3.04 0.002367 
rs6901124 6 109035704 t c 0.0314 4.092 4.27E-05 0.0299 0.584 0.5594 0.0305 3.016 0.002562 
rs78031559 13 69621457 t g 0.9607 -4.412 1.02E-05 0.9612 0.056 0.9553 0.961 -2.878 0.003996 
rs11699273 20 58257735 a g 0.0466 4.238 2.25E-05 0.0463 0.056 0.9553 0.0464 2.847 0.00441 
rs10814589 9 3772674 a g 0.3173 -2.646 0.008143 0.3204 -1.436 0.1511 0.319 -2.828 0.00469 
rs77749998 20 58259307 t c 0.0418 4.193 2.76E-05 0.0438 -0.272 0.7859 0.0429 2.572 0.01012 
rs11696365 20 58255101 t c 0.0415 4.024 5.72E-05 0.0438 -0.295 0.7677 0.0428 2.442 0.0146 
rs9384677 6 108863432 a c 0.0398 3.86 0.0001133 0.042 -0.278 0.7812 0.041 2.347 0.01893 
rs11847901 14 26862055 a g 0.016 4.279 1.87E-05 0.0179 -0.519 0.6035 0.0172 2.272 0.02306 
rs12566058 1 216182811 a g 0.5483 -4.216 2.48E-05 0.5329 0.7 0.4838 0.5396 -2.266 0.02345 
rs11120712 1 216183467 a g 0.465 4.296 1.74E-05 0.473 -0.78 0.4353 0.4695 2.259 0.02391 
rs79205855 14 26855727 c g 0.983 -4.021 5.80E-05 0.9806 0.407 0.6841 0.9815 -2.199 0.02791 
rs11845727 14 26850849 t c 0.9834 -3.945 7.99E-05 0.9814 0.418 0.676 0.9822 -2.142 0.03218 
rs142258091 1 37772341 a t 0.9807 -4.762 1.92E-06 0.9837 1.405 0.16 0.9824 -2.064 0.03905 
rs142632566 1 37747395 t c 0.9807 -4.814 1.48E-06 0.9838 1.486 0.1373 0.9825 -2.037 0.04169 
rs141334771 1 37737497 a g 0.0191 4.781 1.74E-06 0.0161 -1.525 0.1273 0.0174 1.986 0.04704 
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Supplementary Table 4 – All Ischaemic Stroke association statistics for SNPs taken forward to Stage II 
        Stage I         Stage II     Overall   
SNP CHR BP Allele1 Allele2 Freq1 Zscore P.value Freq1 Zscore P.value Freq1 Zscore P.value 
rs11513729 12 112273499 t c 0.4412 4.712 2.46E-06 0.4394 4.693 2.69E-06 0.4402 6.63 3.35E-11 
rs635634 9 136155000 t c 0.1936 4.48 7.47E-06 0.2077 3.818 0.0001348 0.2009 5.86 4.64E-09 
rs532436 9 136149830 a g 0.1928 4.435 9.19E-06 0.2078 3.86 0.0001132 0.2005 5.859 4.65E-09 
rs507666 9 136149399 a g 0.1928 4.433 9.29E-06 0.2078 3.862 0.0001124 0.2005 5.859 4.66E-09 
rs58799304 1 156080444 a t 0.2187 -5.05 4.42E-07 0.2348 -1.684 0.09225 0.2275 -4.644 3.42E-06 
rs12035615 1 156055344 t c 0.2231 -4.767 1.87E-06 0.2227 -1.753 0.07954 0.2229 -4.579 4.68E-06 
rs1440410 4 144158309 a t 0.5364 -4.481 7.43E-06 0.5306 -2.024 0.04296 0.5334 -4.573 4.80E-06 
rs3814314 1 156045183 a t 0.2263 -4.774 1.81E-06 0.2262 -1.739 0.08197 0.2262 -4.573 4.80E-06 
rs181541997 6 47107964 a c 0.0251 4.577 4.71E-06 0.0224 1.816 0.06939 0.0237 4.491 7.09E-06 
rs4322086 9 85787718 a g 0.5302 4.382 1.18E-05 0.5399 2.003 0.04522 0.5352 4.489 7.16E-06 
rs761521 6 47112002 t c 0.0252 4.618 3.88E-06 0.0224 1.746 0.08086 0.0238 4.469 7.86E-06 
rs4618266 4 144036127 t c 0.5608 -4.642 3.45E-06 0.5547 -1.71 0.08726 0.5577 -4.46 8.18E-06 
rs6808694 3 20186297 t c 0.7309 4.42 9.89E-06 0.728 1.923 0.05451 0.7294 4.458 8.27E-06 
rs6805673 3 20185804 a g 0.7271 4.374 1.22E-05 0.7238 1.944 0.05188 0.7254 4.441 8.94E-06 
rs9999826 4 144036457 a g 0.4391 4.635 3.56E-06 0.445 1.678 0.09335 0.4421 4.433 9.30E-06 
rs11759394 6 47115212 t c 0.9747 -4.637 3.53E-06 0.9774 -1.66 0.09688 0.9761 -4.421 9.81E-06 
rs77215829 12 112618346 a c 0.8808 4.519 6.21E-06 0.8751 1.689 0.09122 0.8775 4.225 2.39E-05 
rs138239252 3 41764014 t c 0.1585 -4.2 2.68E-05 0.172 -1.71 0.08727 0.1658 -4.105 4.05E-05 
rs56729913 3 20184853 a t 0.2693 -4.29 1.79E-05 0.2669 -1.509 0.1312 0.2681 -4.071 4.68E-05 
rs6807015 3 41754514 t c 0.8337 4.074 4.62E-05 0.8291 1.769 0.07698 0.8312 4.063 4.85E-05 
rs10010247 4 138466213 t c 0.5888 -5.39 7.04E-08 0.5844 -0.297 0.7664 0.5865 -3.968 7.26E-05 
rs2711814 11 29376425 t c 0.3867 -4.608 4.07E-06 0.3874 -1.054 0.2918 0.3871 -3.966 7.31E-05 
rs2711824 11 29384629 t c 0.6127 4.585 4.54E-06 0.6123 1.055 0.2914 0.6125 3.951 7.79E-05 
rs28695597 4 138458960 a c 0.4098 5.233 1.66E-07 0.4151 0.401 0.6888 0.4125 3.933 8.40E-05 
rs12002585 9 81958890 t c 0.928 4.146 3.39E-05 0.9264 1.353 0.176 0.9272 3.858 0.0001141 
rs56291600 17 38638260 t c 0.9326 -4.613 3.97E-06 0.9278 -0.883 0.3772 0.9301 -3.847 0.0001197 
rs2151155 11 29452159 t c 0.3883 -4.645 3.41E-06 0.3339 -0.85 0.3956 0.3603 -3.845 0.0001207 
rs10867369 9 81980758 t c 0.0731 -4.159 3.20E-05 0.0746 -1.273 0.2031 0.0739 -3.81 0.0001389 
rs17472276 17 38634605 t c 0.9331 -4.658 3.20E-06 0.9275 -0.726 0.4679 0.9302 -3.765 0.0001664 
Page 46 of 48
John Wiley & Sons
Annals of Neurology
This article is protected by copyright. All rights reserved.
rs72819648 17 38635876 t c 0.067 4.662 3.13E-06 0.0725 0.721 0.4708 0.0698 3.765 0.0001667 
rs12551670 9 81957986 a c 0.0725 -4.035 5.46E-05 0.0736 -1.287 0.1981 0.0731 -3.734 0.0001885 
rs1575506 9 85788822 a g 0.3229 4.512 6.44E-06 0.325 0.815 0.4148 0.324 3.728 0.0001933 
rs9817510 3 41813108 t c 0.1676 -3.941 8.10E-05 0.1556 -1.417 0.1565 0.1611 -3.714 0.0002039 
rs61493282 11 102754868 t c 0.0788 4.41 1.04E-05 0.0818 0.859 0.3903 0.0803 3.688 0.0002261 
rs6967828 7 123254157 t c 0.9192 -4.778 1.77E-06 0.9218 -0.414 0.6788 0.9205 -3.625 0.000289 
rs76386877 4 138422617 t c 0.613 -5.539 3.03E-08 0.5862 0.336 0.7367 0.5992 -3.617 0.0002978 
rs73718437 7 123253277 t c 0.0809 4.808 1.52E-06 0.0779 0.352 0.725 0.0794 3.602 0.0003163 
rs6970517 7 123252866 a g 0.0808 4.802 1.57E-06 0.0778 0.349 0.7271 0.0793 3.595 0.0003244 
rs13276017 8 134741381 a c 0.2573 5.16 2.48E-07 0.2528 -0.022 0.9828 0.255 3.578 0.0003458 
rs7865702 9 85790620 t c 0.6731 -4.387 1.15E-05 0.6702 -0.715 0.4745 0.6716 -3.569 0.0003585 
rs72983521 11 102730033 t c 0.9216 -4.265 2.00E-05 0.9205 -0.744 0.4566 0.921 -3.505 0.0004565 
rs113242701 8 73598626 a g 0.9813 -4.817 1.46E-06 0.9838 -0.082 0.9346 0.9826 -3.397 0.0006815 
rs60549974 12 112591821 t c 0.9029 4.097 4.19E-05 0.9062 0.75 0.4531 0.9046 3.392 0.0006941 
rs186861709 8 73630793 a g 0.0171 4.668 3.05E-06 0.0165 0.201 0.8403 0.0168 3.379 0.0007265 
rs2958828 8 134776896 t c 0.2783 4.493 7.03E-06 0.275 0.335 0.7374 0.2766 3.37 0.0007517 
rs10107182 8 59392737 t c 0.6623 -4.13 3.63E-05 0.6526 -0.685 0.4933 0.6573 -3.368 0.0007563 
rs72985562 11 102800278 t g 0.9195 -4.152 3.30E-05 0.9172 -0.61 0.5418 0.9183 -3.33 0.0008697 
rs4738684 8 59393273 a g 0.3401 4.045 5.24E-05 0.348 0.713 0.476 0.3442 3.329 0.0008726 
rs113145661 8 73510416 c g 0.9794 -4.634 3.59E-06 0.9829 -0.231 0.8172 0.9813 -3.327 0.0008782 
rs9297994 8 59392324 a g 0.6614 -4.09 4.32E-05 0.6522 -0.633 0.5268 0.6567 -3.303 0.0009578 
rs41276920 15 90347920 a g 0.0798 -3.96 7.51E-05 0.0764 -0.755 0.45 0.078 -3.3 0.000967 
rs2833496 21 33140026 t c 0.2049 4.673 2.97E-06 0.2137 0.049 0.9611 0.2094 3.29 0.001003 
rs72754570 15 90348979 a g 0.0834 -4.176 2.96E-05 0.0801 -0.5 0.6169 0.0817 -3.284 0.001025 
rs204746 21 33139745 c g 0.7951 -4.676 2.93E-06 0.7862 -0.032 0.9743 0.7905 -3.28 0.001038 
rs9978172 21 33140566 t c 0.2049 4.678 2.90E-06 0.2138 0.031 0.9756 0.2095 3.28 0.001038 
rs2922495 8 134735858 t c 0.3205 4.607 4.08E-06 0.3218 0.022 0.9822 0.3212 3.225 0.00126 
rs7922120 10 115051007 t c 0.0366 4.075 4.61E-05 0.0358 0.55 0.5822 0.0362 3.213 0.001315 
rs118187259 10 115121967 t c 0.0121 4.009 6.10E-05 0.0103 0.675 0.4994 0.0111 3.185 0.001445 
rs7168849 15 90346227 a g 0.9041 3.977 6.98E-05 0.9141 0.581 0.5609 0.9096 3.102 0.001922 
rs12218673 10 115053330 t c 0.0378 4.026 5.67E-05 0.0351 0.425 0.6711 0.0364 3.088 0.002014 
rs8113355 19 49062163 a g 0.7063 -4.427 9.54E-06 0.7067 0.292 0.77 0.7065 -2.835 0.00458 
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CHR, 
chromosome; 
BP, base 
position; 
Freq1, 
frequency of 
Allele1 
 
rs8100256 19 49062157 t g 0.7063 -4.426 9.62E-06 0.7067 0.292 0.7703 0.7065 -2.834 0.004593 
rs4981631 14 27312452 a c 0.7508 4.65 3.33E-06 0.7514 -0.581 0.5611 0.7511 2.822 0.004779 
rs1956818 14 27311163 c g 0.262 -4.584 4.57E-06 0.259 0.55 0.5825 0.2605 -2.798 0.00514 
rs111955440 5 121004011 t c 0.073 -4.808 1.53E-06 0.0736 0.451 0.652 0.0733 -2.789 0.005284 
rs3848542 19 49061724 a g 0.2956 4.365 1.27E-05 0.2954 -0.327 0.7435 0.2955 2.767 0.005655 
rs11696019 2 220664236 t c 0.2147 4.393 1.12E-05 0.2113 -0.46 0.6457 0.2129 2.73 0.006336 
rs982458 2 220663477 t c 0.2138 4.35 1.36E-05 0.2118 -0.468 0.6401 0.2128 2.694 0.007057 
rs13340342 5 120989002 a t 0.9285 4.576 4.75E-06 0.9256 -0.548 0.5836 0.9268 2.564 0.01034 
rs13340387 5 120986986 t c 0.9286 4.42 9.85E-06 0.9257 -0.484 0.6281 0.9269 2.511 0.01202 
rs6720347 2 220645599 t c 0.7667 -4.375 1.21E-05 0.7671 0.779 0.436 0.7669 -2.489 0.01282 
rs111810710 15 24066424 a g 0.0431 4.393 1.12E-05 0.0449 -0.976 0.3291 0.0441 2.262 0.02372 
rs78186832 15 24069618 t c 0.0436 4.403 1.07E-05 0.045 -1.033 0.3017 0.0444 2.227 0.02597 
rs80245324 15 24069688 a t 0.9564 -4.404 1.06E-05 0.955 1.037 0.2997 0.9556 -2.224 0.02614 
rs58673065 7 1885600 a g 0.7641 4.022 5.76E-05 0.7464 -0.823 0.4108 0.7544 2.098 0.03586 
rs11762803 7 1886805 a g 0.7644 3.975 7.05E-05 0.7464 -0.811 0.4171 0.7546 2.075 0.03803 
rs11766945 7 1888054 a g 0.2137 -4.385 1.16E-05 0.2264 1.445 0.1484 0.2206 -1.882 0.05989 
rs2064738 14 27465839 a g 0.7711 4.503 6.69E-06 0.7731 -1.751 0.07992 0.7721 1.88 0.06009 
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